@article{f12748868684472cb11d9fc0e3ee9db3,
title = "FDA guidance on cardiovascular risk of antidiabetic therapies: one decade later",
abstract = "The 2008 FDA guidance for industry on cardiovascular (CV) risk of new antidiabetic therapies arose from a history of CV safety concerns brought to a head by findings with rosiglitazone and the ACCORD trial of intensive glycaemic control.",
author = "Bailey, {Clifford J}",
note = "This is the peer reviewed version of the following article: Bailey, C. J. (2019), FDA guidance on cardiovascular risk of antidiabetic therapies: one decade later. Diabetes Obes Metab. Accepted Author Manuscript, which has been published in final form at https://doi.org/10.1111/dom.13669. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.",
year = "2019",
month = may,
day = "1",
doi = "10.1111/dom.13669",
language = "English",
volume = "21",
pages = "1079--1080",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "5",
}